$EVH earnings report

Evolent Announces Third Quarter 2026 Results. AlphAI read Evolent Health's third quarter 2026 filing as mixed. 2 quarters are on record below.

third quarter 2026

AlphAI · Earnings readEVH · third quarter 2026 · ended September 30, 2026

Evolent Announces Third Quarter 2026 Results

→Mixed quarter

Revenue increased to $725,367 thousand from $479,533 thousand and the Company raised its full-year Adjusted EBITDA range, but quarterly Adjusted EBITDA declined to $34,257 thousand from $38,955 thousand, Adjusted EBITDA margin declined to 4.7% from 8.1%, and the Company reported a net loss attributable to common shareholders of $(23,566) thousand.

Revenue
$725M
Performance Suite revenue, three months ended September 30
$564M
EPS · non-GAAP
$0.06
Full Year 2026 Guidance outlook
$2.6 billion to $2.7 billion

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Revenue, three months ended September 30GAAP$725.4M––
Cost of revenue, three months ended September 30GAAP$636.9M––
Selling, general and administrative expenses, three months ended September 30GAAP$73.12M––
Operating income (loss), three months ended September 30GAAP−$6.19M––
Net loss attributable to common shareholders of Evolent Health, Inc., three months ended September 30GAAP−$23.57M––
Net loss margin, three months ended September 30GAAP(3.2)%––
Loss per share attributable to common shareholders, basic and diluted, three months ended September 30GAAP$(0.21)––
Adjusted cost of revenue, three months ended September 30non-GAAP$635.1M––
Adjusted selling, general and administrative expenses, three months ended September 30non-GAAP$56.00M––
Adjusted EBITDA, three months ended September 30non-GAAP$34.26M––
Adjusted EBITDA margin, three months ended September 30non-GAAP4.7%––
Adjusted income attributable to common shareholders, three months ended September 30non-GAAP$7.30M––
Adjusted income per share attributable to common shareholders, basic and diluted, three months ended September 30non-GAAP$0.06––
Revenue, nine months ended September 30GAAP$1.87B––
Operating income (loss), nine months ended September 30GAAP−$26.35M––
Net loss attributable to common shareholders of Evolent Health, Inc., nine months ended September 30GAAP−$78.56M––
Loss per common share, basic and diluted, nine months ended September 30GAAP$(0.70)––
Adjusted EBITDA, nine months ended September 30non-GAAP$84.37M––
Adjusted EBITDA margin, nine months ended September 30non-GAAP4.5%––
Adjusted income attributable to common shareholders, nine months ended September 30non-GAAP$7.27M––
Adjusted income per share attributable to common shareholders, basic and diluted, nine months ended September 30non-GAAP$0.06––
Medical expense ratio, three months ended September 30other93.0%––
Medical expense ratio excluding Evolent Care Partners, three months ended September 30non-GAAPN/A––
Medical expense ratio, nine months ended September 30other93.9%––
Medical expense ratio excluding Evolent Care Partners, nine months ended September 30non-GAAPN/A––

Segments

SegmentRevenueq/qy/y
Performance Suite revenue, three months ended September 30Revenue from Evolent Care Partners was — in 2026 and $21,550 in 2025; total claims incurred related to specialty care management services were $524,970 in 2026 and $243,908 in 2025.$564.3M––
Specialty Technology and Services Suite revenue, three months ended September 30The Company expanded a relationship with a national payer in Specialty Technology & Services for oncology across 11 additional states.$72.84M––
Administrative Services revenue, three months ended September 30Administrative Services average lives on platform were 1,163 and average PMPM fees were $13.84.$48.29M––
Cases revenue, three months ended September 30Cases were 11 and revenue per case was $3,605.$39.95M––
Performance Suite revenue, nine months ended September 30Total claims incurred related to specialty care management services were $1,288,267.$1.37B––
Specialty Technology and Services Suite revenue, nine months ended September 30The Company reported Specialty Technology and Services Suite average lives on platform of 74,733 for the third quarter.$231.8M––
Administrative Services revenue, nine months ended September 30The Company reported Administrative Services average lives on platform of 1,163 for the third quarter.$145.9M––
Cases revenue, nine months ended September 30The Company reported 11 cases for the third quarter.$124.4M––

Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.

Full Year 2026 Guidance outlook

  • Revenue$2.6 billion to $2.7 billion
  • NoteAdjusted EBITDA: $130.0 million to $135.0 million
  • NoteCash for capitalized expenditures: $26 million to $28 million

Capital returns

  • Repurchase of common stock, nine months ended September 30, 2026: —
  • Payment of preferred dividends, nine months ended September 30, 2026: —
  • Treasury stock, at cost as of September 30, 2026: $(40,306)

What drove it

  • The Company announced one renewal and two new revenue agreements, bringing the year-to-date total to seven.
  • Evolent renewed its largest Surgical Management customer contract for an additional four years.
  • An existing client expanded oncology services across several additional states, representing approximately 1 million Commercial lives, with a January 1, 2027 go-live.
  • The agreement adds Member Navigation across all existing and new lives.
  • The Company stated that rising medical costs impacting health plans continue to drive robust demand for its complex specialty care solutions.
  • Performance Suite average lives on platform were 7,195 and average PMPM fees were $26.14.
  • Specialty Technology and Services Suite average lives on platform were 74,733 and average PMPM fees were $0.32.
  • Average unique members were 39,804.

Concerns

  • Adjusted EBITDA was $34,257, compared with $38,955 in the prior-year quarter, while Adjusted EBITDA margin was 4.7%, compared with 8.1%.
  • Medical expense ratio was 93.0%, compared with 85.0%.
  • Net loss attributable to common shareholders was $(23,566), and operating loss was $(6,188).
  • Interest expense was $(16,996), compared with $(16,475).
  • Long-term debt, net was $969,480 as of September 30, 2026.
  • Accounts receivable, net was $442,766 as of September 30, 2026.
  • The Company identifies increasing risk-sharing arrangements, exposure under performance-based contracts, customer information accuracy, and significant partner concentration among its risks.

What to watch

  • Execution of the approximately 1 million Commercial lives oncology expansion scheduled for a January 1, 2027 go-live.
  • Performance Suite medical expense ratio following the reported 93.0% quarterly level.
  • Delivery against full-year revenue guidance of $2.6 billion to $2.7 billion and Adjusted EBITDA guidance of $130.0 million to $135.0 million.
  • Cash deployed for capitalized expenditures against the expected $26 million to $28 million during 2026.
  • Further expansion of oncology services and Member Navigation with existing clients.
  • The Company's stated intention to deploy up to $50 million toward reducing outstanding indebtedness by the end of the year.

Balance sheet and cash flow

  • Cash and cash equivalents as of September 30, 2026: $148,255
  • Restricted cash as of September 30, 2026: $6,525 current and $1,073 noncurrent
  • Long-term debt, net as of September 30, 2026: $969,480
  • Accounts receivable, net as of September 30, 2026: $442,766
  • Reserve for claims and performance-based arrangements as of September 30, 2026: $376,080
  • Net cash and restricted cash provided by operating activities, nine months ended September 30, 2026: $16,082
  • Investments in internal-use software and purchases of property and equipment, nine months ended September 30, 2026: $(20,464)
  • Net cash and restricted cash used in investing activities, nine months ended September 30, 2026: $(20,164)
  • Repayment of debt, nine months ended September 30, 2026: $(10,000)
  • Net cash and restricted cash used in financing activities, nine months ended September 30, 2026: $(19,517)
  • Net decrease in cash and cash equivalents and restricted cash, nine months ended September 30, 2026: $(24,843)
  • Cash and cash equivalents and restricted cash as of end-of-period: $155,853

Analysis

Third-quarter revenue was $725,367 thousand, compared with $479,533 thousand in the prior-year quarter. Performance Suite revenue was $564,293 thousand, Specialty Technology and Services Suite revenue was $72,837 thousand, Administrative Services revenue was $48,286 thousand, and Cases revenue was $39,951 thousand. The Company described continuing demand from health plans facing rising medical costs and cited a four-year renewal of its largest Surgical Management customer contract, an oncology expansion representing approximately 1 million Commercial lives, and an oncology expansion across 11 additional states with a national payer.

The revenue increase did not translate into improved adjusted profitability in the quarter. Adjusted EBITDA was $34,257 thousand, compared with $38,955 thousand, and Adjusted EBITDA margin was 4.7%, compared with 8.1%. The GAAP operating result was a loss of $(6,188) thousand, and net loss attributable to common shareholders was $(23,566) thousand. Adjusted income attributable to common shareholders was $7,296 thousand and adjusted income per share was $0.06, while GAAP loss per share was $(0.21).

Medical-cost performance is a central issue. The medical expense ratio was 93.0%, compared with 85.0%, while Performance Suite revenue was $564,293 thousand and total claims incurred related to specialty care management services were $524,970 thousand. The Company reported 7,195 Performance Suite average lives on platform and a Performance Suite average PMPM fee of $26.14. Specialty Technology and Services Suite average lives on platform were 74,733, with an average PMPM fee of $0.32.

For the nine months ended September 30, revenue was $1,874,133 thousand and Adjusted EBITDA was $84,374 thousand, compared with $113,362 thousand in the prior-year period. Net cash and restricted cash provided by operating activities was $16,082 thousand, while investments in internal-use software and purchases of property and equipment were $(20,464) thousand. Cash and cash equivalents were $148,255 thousand, and long-term debt, net was $969,480 thousand, as of September 30, 2026.

The Company reiterated full-year 2026 revenue guidance of $2.6 billion to $2.7 billion and raised its Adjusted EBITDA range to $130.0 million to $135.0 million. It expects to deploy $26 million to $28 million in cash for capitalized expenditures during 2026. The key reported operating markers are the medical expense ratio, quarterly Adjusted EBITDA margin, the conversion of new oncology agreements including the January 1, 2027 go-live, and the Company's ability to meet its higher Adjusted EBITDA range while managing its debt and working-capital balances.

Management, verbatim

As health plan customers seek to balance affordability with patient and doctor experience, they continue to turn to Evolent by renewing agreements and in many cases, expanding the work they do with us. That growth and demand from existing clients, as well as strong execution in our 2026 oncology launches, continue to drive strong performance in 2026. Looking ahead, I believe our innovative AI platform and our oncology solution will drive growth and margin expansion for Evolent in the quarters to come.

Seth Blackley, Co-Founder and Chief Executive Officer of Evolent

Not in the filing

stated, not guessed
  • Gross profit and gross margin were not reported.
  • Prior-quarter values and sequential changes were not reported for the presented metrics.
  • A GAAP net income or loss guidance range was not provided.
  • Full-year 2026 guidance for gross margin, operating expenses, and tax rate was not provided.
  • Quarterly segment revenue changes were not reported.
  • Free cash flow was not reported.
  • Current-quarter common-stock repurchases and common-stock dividends were not reported.
  • The previous outlook covered the full year 2026 only, so there is nothing to compare for this quarter.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

second quarter of 2026

AlphAI · Earnings readEVH · second quarter of 2026 · ended June 30, 2026

Evolent reported higher second-quarter revenue and a narrower GAAP net loss, while Adjusted EBITDA and Adjusted EBITDA margin declined and medical expense ratios increased; the company raised 2026 revenue guidance and tightened its Adjusted EBITDA range.

→Mixed quarter

Revenue increased to $ 652,520 from $ 444,328 and net loss narrowed to $ (28,364) from $ (51,090), but Adjusted EBITDA declined to $ 28,050 from $ 37,547, Adjusted EBITDA margin declined to 4.3 % from 8.5 %, and the Medical Expense Ratio increased to 95.3 % from 80.0 %.

Revenue
$653M
EPS · non-GAAP
$ 0.02
Full Year 2026 outlook
$2.6 to $2.7 billion

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
RevenueGAAP$652.5M––
Cost of revenueGAAP$571.7M––
Selling, general and administrative expensesGAAP$68.83M––
Net loss attributable to common shareholders of Evolent Health, Inc.GAAP−$28.36M––
Net loss marginGAAP(4.3) %––
Loss per share attributable to common shareholders of Evolent Health, Inc. Basic and dilutedGAAP$ (0.25)––
Adjusted cost of revenuenon-GAAP$571.0M––
Adjusted selling, general and administrative expensesnon-GAAP$53.48M––
Adjusted EBITDAnon-GAAP$28.05M––
Adjusted EBITDA marginnon-GAAP4.3 %––
Adjusted income (loss) attributable to common shareholdersnon-GAAP$2.23M––
Adjusted income (loss) per share attributable to common shareholders: Basic and dilutednon-GAAP$ 0.02––
Performance Suite Average Lives on Platformother6,715––
Specialty Technology and Services Suite Average Lives on Platformother75,641––
Administrative Services Average Lives on Platformother1,189––
Casesother12––
Average Unique Membersother39,956––
Performance Suite Average PMPM Feesother$ 24.05––
Specialty Technology and Services Suite Average PMPM Feesother0.34––
Administrative Services Average PMPM Feesother13.46––
Revenue per Caseother3,608––
Medical Expense Ratioother95.3 %––
Medical Expense Ratio excluding Evolent Care Partnersother95.3 %––

Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.

Full Year 2026 outlook

  • Revenue$2.6 to $2.7 billion
  • NoteAdjusted EBITDA: $120 to $135 million
  • Notecash for capitalized software development: $25 million to $30 million

What drove it

  • The Company stated that rising medical costs impacting health plans continue to drive robust demand for its complex specialty care solutions.
  • The Company is preparing to launch an Oncology Performance Suite partnership with an existing advanced imaging client by December 2026, subject to certain regulatory approvals.
  • The Oncology Performance Suite partnership will cover approximately 1.5 million lives across Medicaid and Medicare populations spread through 11 states and is expected to generate approximately $300 million in annualized revenue.
  • An existing Specialty Technology & Services Suite regional Blues plan client signed an agreement to add new products and extend existing solutions to additional populations. Implementations are expected during the third and fourth quarters of this year.
  • The Company expects annualized revenue from the expanded Specialty Technology & Services Suite contract to be less than $5 million.
  • The Company expects 2027 revenue growth of over 25% compared to 2026, based on contracts in place today, upcoming launches scheduled, and strong continuing demand for its oncology solution.
  • The Company expects the midpoint of its 2027 Adjusted EBITDA outlook to be at or above $150 million, driven by expected improved Performance Suite care margins and a strong focus on expense reductions.

Concerns

  • Adjusted EBITDA decreased to $ 28,050 from $ 37,547 and Adjusted EBITDA margin declined to 4.3 % from 8.5 %.
  • Medical Expense Ratio increased to 95.3 % from 80.0 %, while Medical Expense Ratio excluding Evolent Care Partners increased to 95.3 % from 84.9 %.
  • Specialty Technology and Services Suite Average Lives on Platform declined to 75,641 from 77,019, Administrative Services Average Lives on Platform declined to 1,189 from 1,231, Cases declined to 12 from 13, and Average Unique Members declined to 39,956 from 40,201.
  • The Company cited significant continued industry headwinds from Medicaid and other client specific membership attrition in its 2027 outlook commentary.
  • The anticipated Oncology Performance Suite partnership launch is subject to certain regulatory approvals.

What to watch

  • Launch timing by December 2026 and regulatory approvals for the Oncology Performance Suite partnership.
  • Implementation timing during the third and fourth quarters of this year for the Specialty Technology & Services Suite client expansion.
  • Performance Suite care margins and expense reductions cited as drivers of the 2027 Adjusted EBITDA outlook.
  • Cash flow conversion and the Company's targeted debt reduction initiatives under evaluation.
  • Medical costs impacting health plans and Medicaid and other client specific membership attrition.

Balance sheet and cash flow

  • Total cash and cash equivalents was $115.7 million as of June 30, 2026.
  • The Company expects to deploy $25 million to $30 million in cash for capitalized software development during 2026.
  • The Company is evaluating targeted debt reduction initiatives.

Analysis

Evolent reported second-quarter revenue of $ 652,520, compared with $ 444,328 in the prior-year period. GAAP net loss attributable to common shareholders narrowed to $ (28,364) from $ (51,090), and net loss margin improved to (4.3) % from (11.5) %. Adjusted income attributable to common shareholders was $ 2,226, compared with adjusted loss attributable to common shareholders of $ (11,013), while adjusted diluted income per share was $ 0.02 compared with adjusted diluted loss per share of $ (0.10).

Profitability metrics were weaker on an adjusted EBITDA basis. Adjusted EBITDA was $ 28,050, compared with $ 37,547, and Adjusted EBITDA margin was 4.3 % compared with 8.5 %. Cost of revenue was $ 571,684 compared with $ 343,943, while the Medical Expense Ratio increased to 95.3 % from 80.0 %. The Medical Expense Ratio excluding Evolent Care Partners was also 95.3 %, compared with 84.9 %. These care-cost metrics are important because management expects improved Performance Suite care margins to support its 2027 Adjusted EBITDA outlook.

Operating metrics show a divergent mix. Performance Suite Average Lives on Platform increased to 6,715 from 6,490, and its Average PMPM Fees increased to $ 24.05 from $ 13.76. Specialty Technology and Services Suite Average Lives on Platform declined to 75,641 from 77,019 and its Average PMPM Fees declined to 0.34 from 0.35. Administrative Services Average Lives on Platform declined to 1,189 from 1,231 and its Average PMPM Fees declined to 13.46 from 15.13. Cases were 12 compared with 13, while Revenue per Case was 3,608 compared with 2,969.

The company raised full-year 2026 revenue guidance to $2.6 to $2.7 billion and tightened its Adjusted EBITDA range to $120 to $135 million. It also expects to deploy $25 million to $30 million in cash for capitalized software development during 2026. Total cash and cash equivalents was $115.7 million as of June 30, 2026. No capital-return activity was disclosed in the provided filing text.

Growth visibility is supported by two partnership announcements. The planned Oncology Performance Suite partnership is expected to cover approximately 1.5 million lives, launch by December 2026 subject to regulatory approvals, and generate approximately $300 million in annualized revenue. A Specialty Technology & Services Suite expansion is expected to be implemented during the third and fourth quarters of this year and generate annualized revenue of less than $5 million. Management's 2027 outlook calls for revenue growth of over 25% compared to 2026 and midpoint Adjusted EBITDA at or above $150 million, but it also cites significant continued industry headwinds from Medicaid and other client specific membership attrition.

Management, verbatim

We believe our results for the second quarter of 2026, our updated 2026 guidance and our 2027 outlook all demonstrate that Evolent is delivering strong growth, profitability and cash flow. We are confident in our emerging AI-led operational model that we believe allows us to deliver excellent client and clinical outcomes, while being highly disciplined with our cost structure.

Seth Blackley, Co-Founder and Chief Executive Officer of Evolent

Looking ahead to 2027, based on contracts in place today, upcoming launches scheduled and the strong continuing demand for our oncology solution, we expect to see revenue growth of over 25% compared to 2026. We expect the midpoint of our 2027 Adjusted EBITDA outlook will be at or above $150 million driven by expected improved Performance Suite care margins and a strong focus on expense reductions, despite significant continued industry headwinds from Medicaid and other client specific membership attrition. We also expect improved cash flow conversion, which, together with targeted debt reduction initiatives we are currently evaluating, we believe provides a clear path to addressing our capital structure and enhancing financial flexibility.

Mario Ramos, Chief Financial Officer of Evolent

Not in the filing

stated, not guessed
  • Prior-quarter comparisons for all reported quarterly metrics.
  • Reported revenue by business segment or product suite.
  • Gross profit or gross margin.
  • GAAP operating income (loss) and operating margin.
  • Operating cash flow.
  • Free cash flow.
  • Debt balance and debt maturity details.
  • Share repurchases, dividends, or other reported capital-return activity.
  • Prior full-year 2026 guidance needed to compare the updated guidance with prior guidance.
  • Quantified 2027 revenue guidance range.
  • Quantified 2027 Adjusted EBITDA guidance range beyond the statement that the midpoint will be at or above $150 million.
  • Guidance for gross margin, operating expenses, and tax rate.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about EVH earnings dates

When is Evolent Health's next earnings date?
AlphAI has no date for EVH yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.